Share This Page
Drugs in ATC Class J01ED
✉ Email this page to a colleague
Drugs in ATC Class: J01ED - Long-acting sulfonamides
Market dynamics and patent landscape for ATC Class J01ED (Long-acting sulfonamides): what patents protect, when exclusivity ends, and where generic entry risks concentrate
ATC Class J01ED (“Long-acting sulfonamides”) is a small, mature segment dominated by older, systemically administered sulfonamides with extended dosing schedules, with patent estates that largely lapsed in key jurisdictions. Commercial dynamics are driven by (1) loss of originator patent cover and (2) regulator-driven substitution among low-cost oral generics and approved combinations. Residual patent risk is concentrated in specific jurisdictions and in product- or process-level protection (formulations, polymorphs, manufacturing methods), not in broad mechanism-of-action claims.
Because “long-acting sulfonamides” is a therapeutic class rather than a single drug, the patent landscape and market exposure vary materially by the exact marketed active ingredients (for example, sulfamethoxazole/trimethoprim combinations can be in different ATC groupings than J01ED, depending on classification rules). Without the specific member substances and the target markets, a complete and accurate patent-and-timeline build across the full class cannot be produced.
Which long-acting sulfonamides sit in ATC J01ED and who sells them?
What ATC J01ED typically includes
J01ED is the ATC category label for “long-acting sulfonamides.” In practice, classification coverage depends on the national ATC implementation and the exact product mapping to ATC codes. For market dynamics, the key question is which active ingredients and dosage forms each payor and regulator treats as J01ED.
Market structure
Class-level supply is typically characterized by:
- Originator-to-generic erosion driven by older filing years
- Pricing anchored by generic interchange and procurement formularies
- Limited late-stage pipeline activity because the class is mature and generics capture most volume
What patents protect long-acting sulfonamides (J01ED) in major jurisdictions?
Are there still “core” patents on sulfonamide mechanism-of-action?
For long-acting sulfonamides marketed for decades, mechanism-of-action and first-in-class compound patents generally expired long ago across the US, EU, and key emerging markets. Remaining patent leverage, when present, tends to be:
- Formulation patents (controlled-release, extended-dosing matrices)
- Solid-state and polymorph patents
- Process patents for synthesis or manufacturing controls
- Secondary patents on specific salts, particle engineering, or stability
- Regulatory-linked exclusivity (where applicable) and patent-term adjustments in the US
Where patent estates concentrate
Across mature small-molecule antibiotics, practical patent barriers often come from:
- Product-specific controlled-release patents (device-free oral extended release)
- Manufacturing patents that are harder for generic filers to “design around” without license
- Narrow use patents, if any exist, tied to specific dosing regimens or patient subsets
When does exclusivity end for long-acting sulfonamides in ATC J01ED?
What drives the exclusivity timeline in this class
Exclusivity outcomes in the J01ED segment depend on:
- Original compound filing date and patent grant timing
- Any patent-term extensions or adjustments (US PTA can shift US end dates)
- EU supplementary protection certificates (SPCs), if product and regulatory data support an SPC
- Final regulatory exclusivities linked to first authorization (rare at class scale for such mature drugs)
Typical pattern for J01ED
The class typically follows a “near-complete patent expiry” profile in core markets, with residual protection expiring at different times by:
- Formulation generations
- Line extensions (new dosage strengths, new release profiles)
- Geographic authorization dates that determine if SPCs were pursued
How many patents cover long-acting sulfonamides, and what are the main claim types?
Patent-count reality check for mature antibiotic classes
At the category level, the visible patent count can appear high because:
- Multiple family members exist (process, intermediate, salt, formulation)
- There are multiple authorized dosage strengths per drug
- Life-cycle patents extend protection on “product variants”
However, for generic entry risk, the material subset is narrow:
- Patents in force for the specific marketed strength and release form in the specific country
- Patents with claim coverage that maps to the generic’s intended label, formulation, and manufacturing route
What generic entry risks exist for ATC J01ED products?
Paragraph IV and challenge landscape
For mature drugs with largely expired primary patents, Paragraph IV risk shifts toward:
- Later-introduced formulation or process patents still in force in a jurisdiction
- Narrowly scoped patents that can be asserted against a specific generic version (same release profile or same manufacturing controls)
Settlement-driven launch timing
Where Orange Book listings remain, generic entry timing is often influenced by:
- First generic filer settlement terms
- Agreed design-around pathways that limit launch triggers (labeling, strength, or release characteristics)
- Court-driven stays tied to patent litigation schedules
What is the Orange Book status of long-acting sulfonamides (J01ED)?
Why Orange Book coverage matters
In the US, the Orange Book lists patents tied to approved NDA/ANDA products. For a class like J01ED, the practical question is whether any listed patents remain for the exact marketed dosage form and strength.
Typical Orange Book pattern for mature sulfonamides
- Some legacy patents have expired
- Remaining listed patents are usually life-cycle formulation/process patents with later expiration dates
- If no Orange Book patents remain for a specific NDC label, generic entry risk is low from a patent standpoint, shifting risk to regulatory quality and bioequivalence
What patent litigation affects long-acting sulfonamides?
Common litigation archetypes
For older antibiotics in mature categories, litigation tends to focus on:
- Alleged infringement of formulation patents (extended-release matrices)
- Validity challenges (obviousness, lack of enablement, indefiniteness)
- Non-infringement via formulation or manufacturing differences
- Enforceability challenges tied to prosecution history or claim scope
Settlement patterns
Settlements in this class, when they occur, typically:
- Delay launch to a later date tied to patent expiration
- Permit launch at risk only after a stay period
- Require label or manufacturing commitments that map to the claimed invention
How do formulation patents change the competitive landscape for J01ED?
Controlled-release and extended-dosing claims
Formulation patents are disproportionately important in long-acting antibiotic categories because they:
- Govern release kinetics and stability
- Define performance targets linked to clinical label claims
- Force generic filers into tighter design-around constraints than for immediate-release products
Solid-state patents and manufacturing controls
Even when the active ingredient is off-patent, generic products can face leverage if:
- Specific polymorph or hydrate form is claimed
- Particle size distribution or amorphous content is claimed
- A manufacturing method step is claimed that is hard to replicate without infringement
Which companies are challenging patents for J01ED long-acting sulfonamides?
Typical generic filers in mature antibiotic categories
In broad antibiotic and small-molecule oral generics, challengers often include:
- Large Indian and other international generic manufacturers when the US or EU markets permit ANDA-style entry
- US-based generic strategists who leverage litigation settlements and AB-rating product placement
Practical reality for J01ED
Actual company-level challenge mapping requires:
- The specific Orange Book listing(s) per NDC
- The associated listed patent numbers
- The PIVIT/market exclusivity records tied to the approved application Without the exact member products, any company enumeration would be incomplete.
How does the J01ED patent landscape compare across US, EU, UK, and key emerging markets?
US: Orange Book driven
- Patent risk tracked by Orange Book listed patents
- Litigation and market-entry timing shaped by ANDA challenges and settlement stays
EU: SPC-driven and national varies
- SPC availability depends on regulatory approval basis and SPC eligibility
- National courts determine infringement outcomes
- Enforcement patterns differ by country’s litigation infrastructure
UK: post-Brexit enforcement still follows patent and exclusivity mechanisms
- UK rights can remain enforceable and can delay entry even when EU rights expire earlier
- Timing differs due to filing and authorization dates
Emerging markets: enforcement and data exclusivity differ
- Risk can be lower when enforcement is weaker
- Or risk can be higher when local filing strategies secure process and formulation patents that persist longer in practice
Commercial dynamics: how patent expiry typically changes pricing, supply, and volume
Price compression mechanics
When patent estates lapse:
- Multiple AB-rated generics enter
- Tender and procurement shift to lowest net price
- Originators often lose share rapidly unless they retain a differentiated formulation advantage
Supply diversification
Mature antibiotics usually see:
- Broad manufacturing footprint by generic companies
- Reduced supply concentration risk over time
- More consistent availability once multiple manufacturers qualify the product
Remaining premium opportunities
Any residual premium exists only if:
- A formulation is still protected (extended release profile)
- A brand retains channel pull due to perceived stability or tolerability
- A patented manufacturing route supports lower-cost scale or better quality attributes (leading to retained contracts)
Key market-entry scenarios for generics if patents remain
Scenario A: No Orange Book patents listed for the target NDC
- Generic entry is often blocked only by regulatory and manufacturing constraints
- Litigation risk is minimal
Scenario B: One or more formulation/process patents remain
- First filer can use Paragraph IV to challenge
- Settlement or design-around can delay or reshape launch
- Labeling and manufacturing controls can become part of the infringement risk management plan
Scenario C: Multiple patents create layered risk
- Litigation can become multi-defendant and multi-patent
- Court schedule and injunction likelihood matter for timing
- Licensing becomes a practical lever if claims are narrow but enforceable
Key takeaways
- J01ED long-acting sulfonamides are a mature, low-growth segment where patent leverage typically shifts from “core compound” to “life-cycle formulation/process” protections.
- In most core markets, primary exclusivity has largely expired; residual generic-entry risk is concentrated in specific strength and release-profile patents.
- Competitive dynamics post-expiry usually follow rapid price compression driven by tendering and AB interchange, with launch timing mainly determined by any remaining formulation/process patent coverage and associated Orange Book listings in the US or SPC/enforcement status in the EU/UK.
FAQs
- What types of patents most commonly block generic entry for extended-release oral sulfonamides?
- How do SPCs affect patent expiration timing for legacy antibiotic products in the EU?
- What evidence is typically used to prove non-infringement for formulation patents tied to release profiles?
- How does settlement timing in ANDA Paragraph IV cases impact real-world generic launch dates?
- Which regulatory pathway differences (NDA vs ANDA vs line extension) most change the patent risk window for this class?
References
- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). ATC classification overview (source context).
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations.
- European Medicines Agency (EMA). Supplementary Protection Certificates (SPC) general information.
More… ↓
